ABCZY:OTC-Abcam plc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 13.88

Change

-0.30 (-2.12)%

Market Cap

USD 2.85B

Volume

0.01M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Germany, the United Kingdom, and internationally. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company also offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-31 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

N/A

USD137.81B 22.42 N/A
CSLLY CSL Limited

-5.35 (-5.53%)

USD85.32B 43.81 29.06
CMXHF CSL Limited

N/A

USD77.36B 39.56 30.68
SBMFF Sino Biopharmaceutical Limited

N/A

USD17.24B 41.21 N/A
SBHMY Sino Biopharmaceutical Limited

N/A

USD17.24B 37.88 N/A
UCBJY UCB SA

N/A

USD15.61B 18.16 N/A
UCBJF UCB SA

+3.26 (+3.89%)

USD15.61B 15.52 N/A
GNMSF Genmab A/S

-5.90 (-2.95%)

USD12.40B 55.74 N/A
BBAGF BB Biotech AG

+250.00 (+500.00%)

USD3.98B 5.30 -20.60
PPTDF PeptiDream Inc

-4.02 (-10.78%)

USD3.97B 235.91 N/A

ETFs Containing ABCZY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -23.74% 40% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.74% 40% F 51% F
Trailing 12 Months  
Capital Gain -5.00% 64% D 72% C-
Dividend Return 0.73% 55% F 9% F
Total Return -4.27% 63% D 70% C-
Trailing 5 Years  
Capital Gain 88.08% 82% B- 84% B
Dividend Return 7.39% 67% D+ 37% F
Total Return 95.46% 83% B 83% B
Average Annual (5 Year Horizon)  
Capital Gain 19.17% 63% D 69% D+
Dividend Return 0.94% 57% F 28% F
Total Return 20.12% 65% D 68% D+
Risk Return Profile  
Volatility (Standard Deviation) 22.79% 91% A- 73% C
Risk Adjusted Return 88.28% 98% A+ 96% A
Market Capitalization 2.85B 95% A 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 35.95 32% F 14% F
Price/Book Ratio 6.31 39% F 12% F
Price / Cash Flow Ratio 40.57 4% F 3% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 11.47% 88% B+ 73% C
Return on Invested Capital 16.62% 68% D+ 78% C+
Return on Assets 7.91% 97% A+ 91% A-
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.74 50% F 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector